Neurológia pre prax 2/2017

Botulinum toxin type A for the migraine prophylactic treatment Botulinum toxin type A for the migraine prophylactic treatment

Chronic migraine (CM) is a neurological disease that remains underdiagnosed and difficult to treat. In the comparison with episodic migraine, patients with CM show a higher degree conditional functional limitation, reduced work productivity and quality of life. This personal and socioeconomic burden emphasizes the urgent need for adequate treatment. Although we commonly use a wide range of oral preventatives in the clinical practice, currently the only the Food and Drug Administration (FDA) approved treatment for CM prevention is onabotulinumtoxin A. In this review, we discuss history and present perspectives of this therapy.

Keywords: chronic migraine, preventative therapy, onabotulinumtoxin A